Literature DB >> 26261585

Prognostic value of transformer 2β expression in prostate cancer.

Yan Diao1, Dong Wu2, Zhijun Dai1, Huafeng Kang1, Ziming Wang3, Xijing Wang1.   

Abstract

BACKGROUND: Deregulation of transformer 2β (Tra2β) has been implicated in several cancers. However, the role of Tra2β expression in prostate cancer (PCa) is unclear. Therefore, this study was to investigate the expression of Tra2β in PCa and evaluated its association with clinicopathological variables and prognosis.
METHODS: Thirty paired fresh PCa samples were analyzed for Tra2β expression by Western blot analysis. Immunohistochemistry (IHC) assay was performed in 160 PCa samples after radical prostatectomy and adjacent non-cancerous tissues. Tra2β protein expression was divided into high expression group and low expression group by IHC. We also investigated the association of Tra2β expression with clinical and pathologic parameters. Kaplan-Meier plots and Cox proportional hazards regression model were used to analyze the association between Tra2β protein expression and prognosis of PCa patients. Our results showed that Tra2β was significantly upregulated in PCa tissues by western blot and IHC.
RESULTS: Our data indicated that high expression of Tra2β was significantly associated with lymph node metastasis (P=0.002), clinical stage (P=0.015), preoperative prostate-specific antigen (P=0.003), Gleason score (P=0.001), and biochemical recurrence (P=0.021). High Tra2β expression was a significant predictor of poor biochemical recurrence free survival and overall survival both in univariate and multivariate analysis.
CONCLUSION: We show that Tra2β was significantly upregulated in PCa patients after radical prostatectomy, and multivariate analysis confirmed Tra2β as an independent prognostic factor.

Entities:  

Keywords:  Prostate cancer; prognosis; transformer 2β

Mesh:

Substances:

Year:  2015        PMID: 26261585      PMCID: PMC4525919     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  15 in total

1.  Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both?

Authors:  Peter R Carroll
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

Review 2.  The utility of prostate-specific antigen in the management of advanced prostate cancer.

Authors:  E David Crawford; Charles L Bennett; Gerald L Andriole; Marc B Garnick; Daniel P Petrylak
Journal:  BJU Int       Date:  2013-07-04       Impact factor: 5.588

3.  Deficiency of the splicing factor Sfrs10 results in early embryonic lethality in mice and has no impact on full-length SMN/Smn splicing.

Authors:  Ylva Mende; Miriam Jakubik; Markus Riessland; Frank Schoenen; Kristina Rossbach; André Kleinridders; Christoph Köhler; Thorsten Buch; Brunhilde Wirth
Journal:  Hum Mol Genet       Date:  2010-02-27       Impact factor: 6.150

4.  Expression levels of hnRNP G and hTra2-beta1 correlate with opposite outcomes in endometrial cancer biology.

Authors:  Yi Qin Ouyang; Axel zur Hausen; Marzenna Orlowska-Volk; Markus Jäger; Herta Bettendorf; Marc Hirschfeld; Xiao Wen Tong; Elmar Stickeler
Journal:  Int J Cancer       Date:  2011-05-01       Impact factor: 7.396

5.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

6.  Splicing factor TRA2B is required for neural progenitor survival.

Authors:  Jacqueline M Roberts; Hanane Ennajdaoui; Carina Edmondson; Brunhilde Wirth; Jeremy R Sanford; Bin Chen
Journal:  J Comp Neurol       Date:  2014-02-01       Impact factor: 3.215

7.  Ets1 and heat shock factor 1 regulate transcription of the Transformer 2β gene in human colon cancer cells.

Authors:  Keisuke Kajita; Yuki Kuwano; Naruka Kitamura; Yuzuru Satake; Kensei Nishida; Ken Kurokawa; Yoko Akaike; Manami Honda; Kiyoshi Masuda; Kazuhito Rokutan
Journal:  J Gastroenterol       Date:  2013-01-30       Impact factor: 7.527

8.  Molecular design of a splicing switch responsive to the RNA binding protein Tra2β.

Authors:  Sushma Nagaraja Grellscheid; Caroline Dalgliesh; Agata Rozanska; David Grellscheid; Cyril F Bourgeois; James Stévenin; David J Elliott
Journal:  Nucleic Acids Res       Date:  2011-06-30       Impact factor: 16.971

9.  Prognostic factors for failure after prostatectomy.

Authors:  Gregory P Swanson; Joseph W Basler
Journal:  J Cancer       Date:  2010-12-07       Impact factor: 4.207

10.  Expression of Tra2 β in Cancer Cells as a Potential Contributory Factor to Neoplasia and Metastasis.

Authors:  Andrew Best; Caroline Dagliesh; Ingrid Ehrmann; Mahsa Kheirollahi-Kouhestani; Alison Tyson-Capper; David J Elliott
Journal:  Int J Cell Biol       Date:  2013-07-08
View more
  8 in total

Review 1.  Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.

Authors:  Laura M Urbanski; Nathan Leclair; Olga Anczuków
Journal:  Wiley Interdiscip Rev RNA       Date:  2018-04-25       Impact factor: 9.957

2.  miR-335 inhibited cell proliferation of lung cancer cells by target Tra2β.

Authors:  Jian Liu; Tingting Bian; Jia Feng; Li Qian; Jianguo Zhang; Daishan Jiang; Qing Zhang; Xiaoli Li; Yifei Liu; Jiahai Shi
Journal:  Cancer Sci       Date:  2017-12-15       Impact factor: 6.716

Review 3.  RNA splicing and splicing regulator changes in prostate cancer pathology.

Authors:  Jennifer Munkley; Karen Livermore; Prabhakar Rajan; David J Elliott
Journal:  Hum Genet       Date:  2017-04-05       Impact factor: 4.132

4.  miR-129 predicts prognosis and inhibits cell growth in human prostate carcinoma.

Authors:  Song Xu; Xiao-Ming Yi; Zheng-Yu Zhang; Jing-Ping Ge; Wen-Quan Zhou
Journal:  Mol Med Rep       Date:  2016-10-19       Impact factor: 2.952

5.  "Stealth dissemination" of macrophage-tumor cell fusions cultured from blood of patients with pancreatic ductal adenocarcinoma.

Authors:  Gary A Clawson; Gail L Matters; Ping Xin; Christopher McGovern; Eric Wafula; Claude dePamphilis; Morgan Meckley; Joyce Wong; Luke Stewart; Christopher D'Jamoos; Naomi Altman; Yuka Imamura Kawasawa; Zhen Du; Loren Honaas; Thomas Abraham
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

6.  Profiling of IgG antibodies targeting unmodified and corresponding citrullinated autoantigens in a multicenter national cohort of early arthritis in Germany.

Authors:  Stefan Vordenbäumen; Ralph Brinks; Patrick Schriek; Angelika Lueking; Jutta G Richter; Petra Budde; Peter Schulz-Knappe; Hans-Dieter Zucht; Johanna Callhoff; Matthias Schneider
Journal:  Arthritis Res Ther       Date:  2020-07-06       Impact factor: 5.156

7.  HnRNPA1 interacts with G-quadruplex in the TRA2B promoter and stimulates its transcription in human colon cancer cells.

Authors:  Tatsuya Nishikawa; Yuki Kuwano; Yumiko Takahara; Kensei Nishida; Kazuhito Rokutan
Journal:  Sci Rep       Date:  2019-07-16       Impact factor: 4.379

Review 8.  Grading Evolution and Contemporary Prognostic Biomarkers of Clinically Significant Prostate Cancer.

Authors:  Konrad Sopyllo; Andrew M Erickson; Tuomas Mirtti
Journal:  Cancers (Basel)       Date:  2021-02-05       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.